Show Search Form
human indexable | ||||||||
---|---|---|---|---|---|---|---|---|
published | ||||||||
registered interest | ||||||||
answer date | ||||||||
date | ||||||||
date tabled | ||||||||
ddp created | ||||||||
answering body |
|
|||||||
question status | Tabled | |||||||
answering dept id | 17 | |||||||
answering dept short name | Health and Social Care | |||||||
answering dept sort name | Health and Social Care | |||||||
ddp modified |
|
|||||||
hansard heading | Rare Diseases: Drugs | |||||||
house id | 1 | |||||||
identifier | 188233 | |||||||
legislature |
|
|||||||
parliament number | 57 | |||||||
question first answered |
|
|||||||
question text | To ask the Secretary of State for Health and Social Care, whether officials in his Department have had discussions with the Scottish Government on the (a) Patient and Clinician Engagement system, (b) its effect on approval rates for new rare disease medicines in Scotland and (c) potential lessons from that system for NHS England. | |||||||
session |
|
|||||||
session number | 1 | |||||||
tabling member constituency | Bury North | |||||||
tabling member printed |
|
|||||||
title | House of Commons Tabled Parliamentary Question 2017/19 188233 | |||||||
type |
|
|||||||
uin | 188233 | |||||||
version | 1 | |||||||
written parliamentary question type | Ordinary | |||||||
answer | answer | |||||||
creator |
|
|||||||
publisher |
|
|||||||
tabling member |
|